+44 20 8123 2220
info@marketpublishers.com

Doose Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/D6E1C88A93F9EN.html
Date: May 2024
Pages: 136
Price: US$ 6,499.00 (Single User License)
ID: D6E1C88A93F9EN

Abstracts

The 7 major doose syndrome markets reached a value of US$ 687.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3,160.7 Million by 2034, exhibiting a growth rate (CAGR) of 14.88% during 2024-2034.

The Doose syndrome market has been comprehensively analyzed in IMARC's new report titled "Doose Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Doose syndrome, also called myoclonic astatic epilepsy (MAE), is a rare form of epilepsy that primarily occurs in children between the ages of 1 and 5 years. It is characterized by a combination of myoclonic, astatic, atonic, and generalized tonic-clonic seizures, which can be accompanied by brief periods of unresponsiveness. The symptoms of this illness vary from child to child but typically include sudden episodes of muscle jerking or spasms, loss of muscle tone leading to falls or drops, and sometimes loss of consciousness. These seizures may occur multiple times a day, significantly impacting a child's development, cognition, and overall quality of life. Diagnosing Doose syndrome can be complex as it requires the exclusion of other forms of epilepsy and careful analysis of the clinical presentation, electroencephalogram (EEG) readings, and the child's medical history. EEG patterns in this condition often show specific abnormalities, such as generalized spike-and-wave discharges or polyspike activity.

The escalating incidence of somatic mutations in the SCN1A gene, which result in the disruption of ion channels in the brain, particularly the cerebral cortex, is primarily driving the Doose syndrome market. Furthermore, the increasing adoption of effective medications, such as valproic acid, benzodiazepines, stiripentol, etc., for managing seizures and reducing their frequency has contributed to a positive market outlook. In

+44 20 8123 2220
info@marketpublishers.com

addition to this, the widespread utilization of ketogenic diets, known for their potential to decrease seizure activity, is bolstering market growth. Moreover, the rising popularity of neurostimulation therapies, including vagus nerve and deep brain stimulation, to control seizures and improve patients' quality of life is acting as another significant growth factor. Besides this, the escalating demand for physical and occupational therapies to enhance muscle strength, coordination, and motor skills in individuals suffering from Doose syndrome is also augmenting the market growth. Furthermore, the growing focus on research and development activities aimed at exploring innovative therapeutic approaches, such as biofeedback techniques, holds substantial promise for the future of the Doose syndrome market. Additionally, the emerging advancements in gene therapy, which targets to correct the underlying genetic abnormalities responsible for the condition, are expected to drive the Doose syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Doose syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Doose syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Doose syndrome market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France

+44 20 8123 2220
info@marketpublishers.com

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Doose syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Doose syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Doose syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights

How has the Doose syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they

+44 20 8123 2220
info@marketpublishers.com

expected to perform till 2034?
What was the country-wise size of the Doose syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Doose syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Doose syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of Doose syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Doose syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Doose syndrome across the seven major markets?
What is the size of the Doose syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Doose syndrome?
What will be the growth rate of patients across the seven major markets?

Doose Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Doose syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Doose syndrome market?
What are the key regulatory events related to the Doose syndrome market?
What is the structure of clinical trial landscape by status related to the Doose syndrome

+44 20 8123 2220
info@marketpublishers.com

market?
What is the structure of clinical trial landscape by phase related to the Doose syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Doose syndrome market?

+44 20 8123 2220
info@marketpublishers.com

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 DOOSE SYNDROME - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 DOOSE SYNDROME - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 DOOSE SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights

+44 20 8123 2220
info@marketpublishers.com

7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)

+44 20 8123 2220
info@marketpublishers.com

7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 DOOSE SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 DOOSE SYNDROME - UNMET NEEDS

10 DOOSE SYNDROME - KEY ENDPOINTS OF TREATMENT

11 DOOSE SYNDROME - MARKETED PRODUCTS

11.1 List of Doose Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.

+44 20 8123 2220
info@marketpublishers.com

12 DOOSE SYNDROME - PIPELINE DRUGS

12.1 List of Doose Syndrome Pipeline Drugs Across the Top 7 Markets
  12.1.1 Drug Name – Company Name
    12.1.1.1 Drug Overview
    12.1.1.2 Mechanism of Action
    12.1.1.3 Clinical Trial Results
    12.1.1.4 Safety and Efficacy
    12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.

13. DOOSE SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. DOOSE SYNDROME – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 DOOSE SYNDROME - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
  15.2.1 Doose Syndrome - Market Size
    15.2.1.1 Market Size (2018-2023)
    15.2.1.2 Market Forecast (2024-2034)
  15.2.2 Doose Syndrome - Market Size by Therapies
    15.2.2.1 Market Size by Therapies (2018-2023)
    15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
  15.3.1 Doose Syndrome - Market Size
    15.3.1.1 Market Size (2018-2023)
    15.3.1.2 Market Forecast (2024-2034)
  15.3.2 Doose Syndrome - Market Size by Therapies
    15.3.2.1 Market Size by Therapies (2018-2023)
    15.3.2.2 Market Forecast by Therapies (2024-2034)
  15.3.3 Doose Syndrome - Access and Reimbursement Overview

+44 20 8123 2220
info@marketpublishers.com

15.4 Market Scenario - Germany
15.4.1 Doose Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Doose Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Doose Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Doose Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Doose Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Doose Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Doose Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Doose Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Doose Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Doose Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Doose Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Doose Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Doose Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Doose Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)

+44 20 8123 2220
info@marketpublishers.com

15.8.3 Doose Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Doose Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Doose Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Doose Syndrome - Access and Reimbursement Overview

16 DOOSE SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 DOOSE SYNDROME MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 DOOSE SYNDROME MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Doose Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: https://marketpublishers.com/r/D6E1C88A93F9EN.html

Price: US$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/D6E1C88A93F9EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com